Tenderwize
Retour à la recherche

Open-house rebate agreements for Natalizumab IV

AOK Rheinland-Pfalz/Saarland - Die Gesundheitskasse·Eisenberg, Germany·Deadline Mar 31, 2027 · 163 days left·Open·Supplies
Titre original de l'avis

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge zum Wirkstoff Natalizumab, i.v. Darreichungsform, ATC L04AG03

46/100

Score d'opportunité

Needs reviewMedium complexity
SuppliesOpen
Pourquoi ce score ?

Opportunité

46 / 100

Complexité

58 / 100

Facteurs de risque

Submission must be in original form and electronic submission is not allowed.

Only authorised and marketable medicines in Germany may be supplied; if Lauer-Taxe evidence is missing, additional AMIc...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Informations clés

Pouvoir adjudicateur
AOK Rheinland-Pfalz/Saarland - Die Gesundheitskasse
Pays
Allemagne
CPV
33600000 - Pharmaceutical products
Date limite
Mar 31, 2027

Aperçu

Moderate opportunity

Faits clés

  • Supplies contract
  • 1 lot
  • Duration until May 2027
  • Supply of pharmaceutical products under an open-house rebate agreement for Natalizumab, intravenous dosage form, ATC L04AG03.
  • Non-exclusive contract model with uniform terms for all participants; no individual negotiations.
Afficher le résumé complet

Open-house supply arrangement for Natalizumab (IV form, ATC L04AG03) offered by AOK Rheinland-Pfalz/Saarland. The notice states this is a non-exclusive, open-house model with uniform terms, no individual negotiations, and monthly entry possible during a maximum 24-month period. Submission is by original documents, electronic submission is not allowed, and the provided data indicates no contract value was published. The notice also states that children’s medicines listed by BfArM under §35(5a) SGB V are excluded.

Risques

Submission must be in original form and electronic submission is not allowed.

Only authorised and marketable medicines in Germany may be supplied; if Lauer-Taxe evidence is missing, additional AMIc...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Only authorised and marketable medicines in Germany may be supplied under the contract.

Administrative

  • If the medicine is not listed in Lauer-Taxe at submission time, the bidder must provide an extract from the public AMIce database and, where needed, additional supporting...
  • Submission must be in original form; electronic submission is not allowed.

Acheteur

Localisation

Eisenberg, DEU

Profil acheteur

Ouvrir le profil

Identifiant

DE271900642

Activité

Health

Lots (1)

LOT-0001

Open-house rebate agreements for Natalizumab IV

Single lot covering non-exclusive open-house rebate agreements for medicinal products containing Natalizumab in intravenous dosage form (ATC L04AG03). The buyer states that all interested pharmaceutical companies may join under identical conditions, without selection decision or individual negotiation. The lot excludes medicines listed as children’s medicines under the BfArM list referenced in the notice. Contract duration is up to 24 months, with the earliest start on 2025-06-01 and monthly entry possible; contracts end no later than 24 months after the earliest start date. The lot-level value is not provided.

SuppliesEU fundedElectronic submission

Localisation

Eisenberg, Germany

Durée

May 2025 - May 2027

Catégorie

Pharmaceutical products

Date limite

Deadline Mar 31, 2027

Détails de la procédure

Date de publication
10 Apr 2025
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
235853-2025

Documents (1)

Appels d'offres similaires